Erste Group downgraded Regeneron to Hold from Buy. The company recently suffered a preliminary court defeat in a legal dispute with Amgen, which means Amgen can sell Eleya, for which Regeneron claims patents. Regeneron’s sales growth will be impaired as a result, as will the upside potential of the shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi announce Dupixent approved in U.S. for COPD patients
- Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
- Biotech Alert: Searches spiking for these stocks today
- Morgan Stanley backs Overweight on Regeneron after Amgen temporarily enjoined
- Closing Bell Movers: Micron rallies 13% after Q4 earnings beat